Tuning, Rather than Blocking, Immunity in IBD
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Tuning, Rather than Blocking, Immunity in IBD” inside PodZeus.
This episode of The BioReport explores Abivax's novel approach to treating inflammatory bowel disease (IBD), focusing on its lead candidate, obifazomod—a once-failed HIV drug now repurposed as a first-in-class oral therapy for ulcerative colitis and Crohn's disease. CEO Mark DeGaradel explains how obifazomod works by modulating microRNA-124 to gently 'tune' the immune system rather than broadly suppress it, offering a potentially safer, more durable alternative to current immunosuppressive treatments. The drug has shown promising results in a large Phase 3 trial, including consistent efficacy across patient subgroups—such as those resistant to JAK inhibitors—and a favorable safety profile with minimal adverse events. The episode highlights the drug’s unique mechanism, its potential for combination therapies, and its strong adherence incentives due to rapid symptom return upon discontinuation. Investors have responded positively to the unmet medical need, innovative mechanism, and strong real-world data, fueling Abivax’s $1.5 billion in funding. The company plans to file for FDA approval by end of 2026 and launch in the U.S. in Q3 2027, while seeking international partners for commercialization. Key takeaways include: 1) Obifazomod offers a 'tune, not block' immune strategy via microRNA-124 modulation, reducing inflammation without over-suppressing immunity. 2) It shows durable remission potential with low discontinuation rates and a favorable safety profile, especially in high-risk, treatment-experienced patients. 3) The drug’s oral, once-daily format and self-enforcing adherence (due to symptom rebound) improve real-world usability. 4) Early data suggest anti-fibrotic effects, which could be transformative for Crohn’s patients prone to strictures. 5) Abivax’s success stems from a rare mechanism of action, strong clinical data, and investor confidence in a high-unmet-need space. The overall sentiment is highly positive, reflecting optimism about a paradigm shift in IBD treatment.
Obifazomod modulates microRNA-124 to 'tune' the immune system rather than suppress it, offering a safer, more durable alternative to current immunosuppressive IBD therapies.
The drug shows consistent efficacy across diverse patient populations—including JAK-resistant patients—with minimal adverse events and high remission rates in long-term follow-up.
Its oral, once-daily format and self-enforcing adherence (symptoms return quickly if missed) improve real-world use and reduce treatment cycling.
Early data suggest anti-fibrotic effects, potentially reducing the need for surgery in Crohn’s patients with strictures.
Abivax’s innovative mechanism and strong clinical results have attracted significant investor interest, enabling a $1.5 billion funding round and a planned U.S. launch in Q3 2027.
The Problem with Current IBD Treatments
“The treatment of inflammatory bowel disease currently relies on immunosuppressive therapies that often lose effectiveness, carry infection risk, and drive high-treatment cycling.”
Abivax's Novel Approach: Tuning, Not Blocking Immunity
“It's not an immunoblocker. It's an immunostabilizer.”
From HIV to IBD: A Serendipitous Discovery
“It was really through a functional testing that Obifazimod was found to boost the expression of a specific microRNA, microRNA124.”
Clinical Results and Safety Profile
The Phase 3 trial results for obifazomod in ulcerative colitis are discussed, showing statistically significant clinical and endoscopic remission. Safety data are highly encouraging, with only mild headaches reported and no serious adverse events or new signals in long-term monitoring.
Adherence and Long-Term Efficacy
The episode explores how obifazomod’s mechanism may promote adherence—patients feel worse quickly if they miss doses—leading to higher retention. Long-term data from open-label extensions show ~90% remission rates and half the dropout rate of current therapies.
“It's not an immunoblocker. It's an immunostabilizer.”
“Obifazomod may also have an anti-fibrotic effect, which could be particularly helpful in Crohn's patients because 40% of Crohn's patients develop strictures.”
“If you are not inflamed, nothing happens. If your tissue is inflamed or you have a systemic inflammation, your inflammation is going to come down progressively.”
Host
Guest
Obifazomod
product
Abivax
organization
Ulcerative Colitis
other
Crohn's Disease
other
Mark DeGaradel
person
MicroRNA-124
other
Phase 3 Clinical Trial
other
HIV
other
ECHO Congress
other
FDA
organization
Targeting Psychosis in Alzheimer’s Disease
The Bio Report • 22m • 4/1/2026
Intercepting Cancer When DNA Surveillance Fails
The Bio Report • 39m • 4/8/2026
Slowing Disability in MS
The Bio Report • 29m • 4/22/2026
An Off-the-Shelf Cell Therapy to Calm Cytokine Storms
The Bio Report • 28m • 4/29/2026
Addressing Treatment Gaps in Gout
The Bio Report • 36m • 5/6/2026
Get the full intelligence
Search transcripts, export clips, track mentions, and explore all topics from “Tuning, Rather than Blocking, Immunity in IBD” inside PodZeus.
Start discovering podcast insights today
Start with a 7-day trial and explore a growing catalog of popular podcasts. No credit card required.
No credit card required • 7-day trial • Cancel anytime